The effect of prophylactic treatment with risedronate on stress fracture incidence among infantry recruits

Charles Milgrom, Aharon Finestone, Victor Novack, David Pereg, Yakov Goldich, Yitshak Kreiss, Eyal Zimlichman, Shai Kaufman, Meir Liebergall, David Burr

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

When subjected to strains or strain rates higher than usual, the bone remodels to repair microdamage and to strengthen itself. During the initial resorption phase of remodeling, the bone is transitorily weakened and microdamage can accumulate leading to stress fracture. To determine whether short-term suppression of bone turnover using bisphosphonates can prevent the initial loss of bone during the remodeling response to high bone strain and strain rates and potentially prevent stress fracture, we conducted a randomized, double-blind, placebo-controlled trial of 324 new infantry recruits known to be at high risk for stress fracture. Recruits were given a loading dose of 30 mg of risedronate or placebo daily for 10 doses during the first 2 weeks of basic training and then a once a week maintenance dose for the following 12 weeks. Recruits were monitored by biweekly orthopedic examinations during 15 weeks of basic training for stress fractures. Bone scans for suspected tibial and femoral stress fractures and radiographs for suspected metatarsal stress fractures were used to verify stress fracture occurrence. By the intention-to-treat analysis and per-protocol analysis, there was no statistically significant difference in the tibial, femoral, metatarsal, or total stress fracture incidence between the treatment group and the placebo. We conclude that prophylactic treatment with risedronate in a training population at high risk for stress fracture using a maintenance dosage for the treatment of osteoporosis does not lower stress fracture risk.

Original languageEnglish
Pages (from-to)418-424
Number of pages7
JournalBone
Volume35
Issue number2
DOIs
StatePublished - Aug 2004

Fingerprint

Stress Fractures
Incidence
Bone Remodeling
Therapeutics
Metatarsal Bones
Placebos
Bone and Bones
Risedronate Sodium
Intention to Treat Analysis
Femoral Fractures
Diphosphonates
Thigh
Osteoporosis
Orthopedics
Maintenance

Keywords

  • Bisphosphonates
  • Microdamage
  • Remodeling
  • Stress fracture

ASJC Scopus subject areas

  • Physiology
  • Hematology

Cite this

Milgrom, C., Finestone, A., Novack, V., Pereg, D., Goldich, Y., Kreiss, Y., ... Burr, D. (2004). The effect of prophylactic treatment with risedronate on stress fracture incidence among infantry recruits. Bone, 35(2), 418-424. https://doi.org/10.1016/j.bone.2004.04.016

The effect of prophylactic treatment with risedronate on stress fracture incidence among infantry recruits. / Milgrom, Charles; Finestone, Aharon; Novack, Victor; Pereg, David; Goldich, Yakov; Kreiss, Yitshak; Zimlichman, Eyal; Kaufman, Shai; Liebergall, Meir; Burr, David.

In: Bone, Vol. 35, No. 2, 08.2004, p. 418-424.

Research output: Contribution to journalArticle

Milgrom, C, Finestone, A, Novack, V, Pereg, D, Goldich, Y, Kreiss, Y, Zimlichman, E, Kaufman, S, Liebergall, M & Burr, D 2004, 'The effect of prophylactic treatment with risedronate on stress fracture incidence among infantry recruits', Bone, vol. 35, no. 2, pp. 418-424. https://doi.org/10.1016/j.bone.2004.04.016
Milgrom, Charles ; Finestone, Aharon ; Novack, Victor ; Pereg, David ; Goldich, Yakov ; Kreiss, Yitshak ; Zimlichman, Eyal ; Kaufman, Shai ; Liebergall, Meir ; Burr, David. / The effect of prophylactic treatment with risedronate on stress fracture incidence among infantry recruits. In: Bone. 2004 ; Vol. 35, No. 2. pp. 418-424.
@article{b82b396bf4fd4ea983c020f967081ee1,
title = "The effect of prophylactic treatment with risedronate on stress fracture incidence among infantry recruits",
abstract = "When subjected to strains or strain rates higher than usual, the bone remodels to repair microdamage and to strengthen itself. During the initial resorption phase of remodeling, the bone is transitorily weakened and microdamage can accumulate leading to stress fracture. To determine whether short-term suppression of bone turnover using bisphosphonates can prevent the initial loss of bone during the remodeling response to high bone strain and strain rates and potentially prevent stress fracture, we conducted a randomized, double-blind, placebo-controlled trial of 324 new infantry recruits known to be at high risk for stress fracture. Recruits were given a loading dose of 30 mg of risedronate or placebo daily for 10 doses during the first 2 weeks of basic training and then a once a week maintenance dose for the following 12 weeks. Recruits were monitored by biweekly orthopedic examinations during 15 weeks of basic training for stress fractures. Bone scans for suspected tibial and femoral stress fractures and radiographs for suspected metatarsal stress fractures were used to verify stress fracture occurrence. By the intention-to-treat analysis and per-protocol analysis, there was no statistically significant difference in the tibial, femoral, metatarsal, or total stress fracture incidence between the treatment group and the placebo. We conclude that prophylactic treatment with risedronate in a training population at high risk for stress fracture using a maintenance dosage for the treatment of osteoporosis does not lower stress fracture risk.",
keywords = "Bisphosphonates, Microdamage, Remodeling, Stress fracture",
author = "Charles Milgrom and Aharon Finestone and Victor Novack and David Pereg and Yakov Goldich and Yitshak Kreiss and Eyal Zimlichman and Shai Kaufman and Meir Liebergall and David Burr",
year = "2004",
month = "8",
doi = "10.1016/j.bone.2004.04.016",
language = "English",
volume = "35",
pages = "418--424",
journal = "Bone",
issn = "8756-3282",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - The effect of prophylactic treatment with risedronate on stress fracture incidence among infantry recruits

AU - Milgrom, Charles

AU - Finestone, Aharon

AU - Novack, Victor

AU - Pereg, David

AU - Goldich, Yakov

AU - Kreiss, Yitshak

AU - Zimlichman, Eyal

AU - Kaufman, Shai

AU - Liebergall, Meir

AU - Burr, David

PY - 2004/8

Y1 - 2004/8

N2 - When subjected to strains or strain rates higher than usual, the bone remodels to repair microdamage and to strengthen itself. During the initial resorption phase of remodeling, the bone is transitorily weakened and microdamage can accumulate leading to stress fracture. To determine whether short-term suppression of bone turnover using bisphosphonates can prevent the initial loss of bone during the remodeling response to high bone strain and strain rates and potentially prevent stress fracture, we conducted a randomized, double-blind, placebo-controlled trial of 324 new infantry recruits known to be at high risk for stress fracture. Recruits were given a loading dose of 30 mg of risedronate or placebo daily for 10 doses during the first 2 weeks of basic training and then a once a week maintenance dose for the following 12 weeks. Recruits were monitored by biweekly orthopedic examinations during 15 weeks of basic training for stress fractures. Bone scans for suspected tibial and femoral stress fractures and radiographs for suspected metatarsal stress fractures were used to verify stress fracture occurrence. By the intention-to-treat analysis and per-protocol analysis, there was no statistically significant difference in the tibial, femoral, metatarsal, or total stress fracture incidence between the treatment group and the placebo. We conclude that prophylactic treatment with risedronate in a training population at high risk for stress fracture using a maintenance dosage for the treatment of osteoporosis does not lower stress fracture risk.

AB - When subjected to strains or strain rates higher than usual, the bone remodels to repair microdamage and to strengthen itself. During the initial resorption phase of remodeling, the bone is transitorily weakened and microdamage can accumulate leading to stress fracture. To determine whether short-term suppression of bone turnover using bisphosphonates can prevent the initial loss of bone during the remodeling response to high bone strain and strain rates and potentially prevent stress fracture, we conducted a randomized, double-blind, placebo-controlled trial of 324 new infantry recruits known to be at high risk for stress fracture. Recruits were given a loading dose of 30 mg of risedronate or placebo daily for 10 doses during the first 2 weeks of basic training and then a once a week maintenance dose for the following 12 weeks. Recruits were monitored by biweekly orthopedic examinations during 15 weeks of basic training for stress fractures. Bone scans for suspected tibial and femoral stress fractures and radiographs for suspected metatarsal stress fractures were used to verify stress fracture occurrence. By the intention-to-treat analysis and per-protocol analysis, there was no statistically significant difference in the tibial, femoral, metatarsal, or total stress fracture incidence between the treatment group and the placebo. We conclude that prophylactic treatment with risedronate in a training population at high risk for stress fracture using a maintenance dosage for the treatment of osteoporosis does not lower stress fracture risk.

KW - Bisphosphonates

KW - Microdamage

KW - Remodeling

KW - Stress fracture

UR - http://www.scopus.com/inward/record.url?scp=3242702431&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3242702431&partnerID=8YFLogxK

U2 - 10.1016/j.bone.2004.04.016

DO - 10.1016/j.bone.2004.04.016

M3 - Article

C2 - 15268892

AN - SCOPUS:3242702431

VL - 35

SP - 418

EP - 424

JO - Bone

JF - Bone

SN - 8756-3282

IS - 2

ER -